TY -的A2 -德考克,Joery AU -李,Bing AU - Cheng Yu AU - Yu Songyan盟——藏,李盟-阴,雅琦盟——刘,捷洁盟——张、林盟——μ、翳明PY - 2019 DA - 2019/11/03 TI -人类脐Cord-Derived间充质干细胞疗法改善非酒精性脂肪肝病在肥胖2型糖尿病小鼠SP - 8628027六世- 2019 AB -非酒精性脂肪肝病(NAFLD)是越来越普遍患者2型糖尿病(T2DM)病人体内。两个条件可以协同作用产生不利的结果。然而,非酒精性脂肪肝患者和2型糖尿病的治疗选项目前有限的。人类脐cord-derived间充质干细胞(UC-MSCs)显示潜力治疗糖尿病和肝脏疾病,如肝硬化和暴发性肝衰竭。本研究旨在调查的影响人类UC-MSCs NAFLD和2型糖尿病小鼠模型,以obesity-induced高血糖症,dyslipidaemia,肝脂肪变性,肝障碍。Thirty-week-old雄性C57BL / 6 db / db小鼠被注入了人类UC-MSCs或磷酸盐(PBS)通过尾静脉一周一次了六个星期。的同龄雄性C57BL / 6 db / +野生型小鼠被用作控制。每周测量体重和随机血糖。一周后第六输液,腹腔内葡萄糖耐量测试和胰岛素耐受性测试执行,血液和肝脏收获生化和组织病理学检查。定量实时逆转录酶聚合酶链反应(存在),免疫荧光染色和免疫印迹进行监控的表达脂质代谢和监管pathway-related基因。 UC-MSC infusions significantly ameliorated hyperglycaemia, attenuated the elevation of hepatic transaminases, and decreased lipid contents, including triglyceride, total cholesterol, and low-density lipoprotein cholesterol. Moreover, histological lesions in the liver diminished markedly, as evidenced by reduced lipid accumulation and attenuated hepatic steatosis. Mechanistically, UC-MSCs were found to regulate lipid metabolism by increasing the expression of fatty acid oxidation-related genes and inhibiting the expression of lipogenesis-related genes, which were associated with the upregulation of the HNF4 α-CES2途径。我们的结果表明,人类UC-MSCs可以改善非酒精性脂肪肝和反向代谢综合征在db / db老鼠。因此,UC-MSCs可能作为小说剂治疗2型糖尿病患者非酒精性脂肪肝。SN - 1687 - 966 - 2019/8628027 / 10.1155 x你——https://doi.org/10.1155/2019/8628027——摩根富林明-干细胞国际PB - Hindawi KW - ER